Lidocaine and Dexmedetomidine Infusion and Their Combination on Perioperative Pain in Patients Undergoing Video-Assisted Thoracoscopic Surgery

Ain Shams University

Status: Enrolling

Conditions: Perioperative Pain; Dexmedetomidine; Infusion; Video-Assisted Thoracoscopic Surgery; Lidocaine

Treatments: Drug: Dexmedetomidine; Drug: Lidocaine and Dexmedetomidine; Drug: Lidocaine

Study type: Interventional

Funder types: Other

Identifiers

NCT06837519

FMASU R22/2025

Details and patient eligibility

About

This study aims to compare lidocaine and dexmedetomidine infusion and their combination on perioperative pain in patients undergoing video-assisted thoracoscopic surgery.

Full description

Video-assisted thoracoscopic surgery (VATS) is a minimally invasive procedure allowing the reduction of surgical stress. However, postoperative pain management is crucial for patients undergoing VATS, as inadequate pain control can lead to complications (such as lung atelectasis), prolonged recovery, and decreased patient satisfaction.

Dexmedetomidine has shown positive effects on postoperative pain intensity, opioid consumption and other recovery parameters, such as postoperative nausea and vomiting (PONV), and speed of recovery.

Lidocaine has exhibited an excellent safety profile when administered as a low-dose infusion for cancer or non-cancer chronic pain.

Enrollment: 75 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age ≥18 years old.
• Both sexes.
• American Society of Anesthesiologists (ASA) physical status of I, II.
• Patients undergoing video-assisted thoracoscopic surgery (VATS) under general anesthesia.

Exclusion criteria

• Hypersensitivity to any of the used drugs.
• Coagulation disorder.
• Body mass index >35 kg/m2.
• History of chronic pain requiring daily opioids/steroids/clonidine/other α2 agonist/analgesics or any drugs acting on the central nervous system during the previous 2 weeks, and drug/alcohol abuse.
• Contraindication to the use of local anesthetics.
• Cardiovascular disease.
• Severe respiratory, renal or hepatic impairment.
• Insulin-dependent diabetes mellitus.
• Central nervous system or psychiatric disease.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

75 participants in 3 patient groups

Lidocaine group

Experimental group

Description:

Patients will receive lidocaine 0.3 mg/kg over 10 min loading, 0.3 mg/kg/h infusion after induction of anesthesia as maintenance dose till 10 min before the end of the operation plus saline 0.9% with same rate of dexmedetomidine

Treatment:

Drug: Lidocaine

Dexmedetomidine group

Experimental group

Description:

Patients will receive dexmedetomidine 0.5 μg/kg infusion over 10 min as a loading dose then 0.5 μg/kg/h after induction of anesthesia as maintenance dose till 10 min before the end of the operation plus saline 0.9% with same rate of lidocaine.

Treatment:

Drug: Dexmedetomidine

Lidocaine and Dexmedetomidine group

Experimental group

Description:

Patients will receive lidocaine (0.3 mg/kg in 10 min loading, 0.3 mg/kg/h infusion) and dexmedetomidine infusions (0.5 μg/kg infusion over 10 min as a loading dose then 0.5 μg/kg/h) till 10 min before the end of the operation.

Treatment:

Drug: Lidocaine and Dexmedetomidine